CAREERS CONTACT US OUR STORY MEDICINES RESEARCH & DEVELOPMENT IMPACT INVESTORS & MEDIA Our Early-Stage Compounds Exelixis has a diverse portfolio of small molecule and biologics programs moving forward, covering a broad range of targets and therapeutic modalities. We are committed to further enhancing our early-stage pipeline and expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. R & D Pipeline Overview Early-Stage Compounds Cabozantinib Pipeline Other Partnered Programs Clinical Trials Program Name Mechanism Discovery/ Preclinical IND Phase 1a Phase 1b Phase 2/3 XL092 Next-generation TKI targeting MET/ VEGFR/AXL/MER XL102 Potent, selective, orally bioavailable CDK7 inhibitor XB002 Next-generation tissue factor-targeting ADC XL114 CBM pathway inhibitor Aurigene Collaboration Programs Undisclosed StemSynergy Collaboration Program CK1α activators StemSynergy Collaboration Program Selective notch inhibitors STORM Therapeutics Collaboration Program ADAR1 STORM Therapeutics Collaboration Program Undisclosed Exelixis Discovery Programs Undisclosed Biologics Programs Invenra, NBE Therapeutics, Catalent, Gamamabs (AMRII) & Adagene Collaborations Undisclosed TKI = tyrosine kinase inhibitor CDK7 = cyclin-dependent kinase 7 ADC = antibody-drug conjugate CBM = CARD11-BCL10-MALT1 CK1α = casein kinase 1 alpha IND = Investigational New Drug application Cabozantinib Pipeline Explore the diverse development program for our flagship molecule LEARN MORE OUR STORY Mission Leadership Board of Directors Collaborations MEDICINES Our Medicines Access RESEARCH & DEVELOPMENT Research & Development Pipeline Clinical Trials IMPACT Why Cancer? Patient Stories Grants & Giving Corporate Responsibility Environmental, Social & Governance Statement on COVID-19 INVESTORS & MEDIA Investors Overview News & Events Stock Information Financial Information Investor Resources Corporate Governance Contact IR © Exelixis, Inc. 2021 Ethics & Compliance Privacy Terms of Use You can learn more from our Privacy Statement. OK